MedTrace Logo

Blepharospasm Patient Survey for Patients With Blepharospasm

NCT01686061 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 124

Last updated 2022-10-28

No results posted yet for this study

Summary

The purpose of this survey is to collect detailed information on patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA, including how often they are treated with botulinum toxin, how long their treatment lasts, how satisfied they are with their treatment, and if there is any improvement in their symptoms with the treatment.

Conditions

  • Blepharospasm

Interventions

OTHER

No intervention- only one time survey

Sponsors & Collaborators

  • Merz North America, Inc.

    collaborator INDUSTRY

  • Merz Pharmaceuticals GmbH

    lead INDUSTRY

Principal Investigators

  • Micki Seoane · Merz Pharmaceutical, LLC

Eligibility

Min Age
18 Years
Max Age
81 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01686061 on ClinicalTrials.gov